European Surgical Research
Original Paper
Linomide and Antibody-Targeted Superantigen Therapy Abolishes Formation of Liver Metastases in MiceLiu Q.a · Klintman D.a · Corbascio M.a · Ekberg H.a · Hedlund G.b · Forsberg G.b · Thorlacius H.aaDepartment of Surgery, Malmö University Hospital, Lund University, Malmö, and bActive Biotech Research, Lund, Sweden
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 02, 2002
Accepted: April 08, 2003
Published online: November 06, 2003
Issue release date: November – December
Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 1
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Abstract
Hematogenous spread of tumor cells and metastasis formation in the liver are insidious aspects of cancer progression and are not frequently amenable to curative treatment. We examined the effect of Linomide and antibody-targeted therapy against the formation of hepatic metastases in vivo. For this purpose, syngenic B16 melanoma cells transfected with GA733-2 (a human colon cancer cell surface antigen) were injected into a mesenteric vein of C57/Bl6 mice. To test bacterial superantigen (Sag) targeting for immunotherapy of liver metastases, we used genetically fused proteins consisting of SEA and a Fab moiety of a GA733-2 tumor-reactive antibody (C215Fab-SEA). Linomide dose-dependently reduced hepatic metastases, and at 300 mg/kg this reduction was more than 80%. Treatment with C215Fab-SEA decreased metastases formation by 49% and the combination of Linomide and C215Fab-SEA was found to completely abolish liver metastases (>99% reduction). Taken together, our novel data suggest that Linomide and antibody-targeted superantigen therapy individually markedly reduce and together abolish liver metastases. Considering that current therapy of hepatic metastases is mainly limited to surgical resection in a subgroup of patients, these findings indicate that Linomide alone or in combination with antibody-targeted superantigen may provide a novel approach against liver metastases.
© 2003 S. Karger AG, Basel
Related Articles:
References
- Borgström P, Torres Filho IP, Hartley-Asp B: Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by quinoline-3-carboxamide, Linomide. Anticancer Res 1995;15:719–728.
-
Harning R, Szalay J: A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Vis Sci 1998;29:1505–1510.
- Ziche M, Donnini S, Morbidelli L, Parenti A, Gasparini G, Ledda F: Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer 1998;77:1123–1129.
- Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499–1504.
- Bai XF, Shi FD, Zhu J, Xiao BG, Hedlund G, Link H: Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J Neuroimmunol 1997;76:177–184.
- Lehmann D, Karussis DM, Fluresco D, Mizrachi-Koll R, Ovadia H, Shezen E, Kalland T, Abramsky O: Immunomodulation of autoimmunity by Linomide: Inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol 1997;74:102–110.
- Kalland T: Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 1986;46:3018–3022.
- Berlin-Rufenach C, Otto F, Mathies M, Westermann J, Owen MJ, Hamann A, Hogg N: Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med 1999;189:1467–1478.
-
Davignon D, Martz E, Reynolds K, Kurzinger K, Springer TA: Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): Mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions. J Immunol 1990;127:590–595.
External Resources
- Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, Ohashi PS, Mak T, Hickstein DD: LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med 1996;183:1415–1426.
- Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forsberg C, Lind P, Kalland T: Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 1994;91:8945–8949.
- Johnson HM, Russell JK, Pontzer CH: Staphylococcal enterotoxin microbial superantigens. Faseb J 1991;5:2706–2712.
- Kalland T, Hedlund G, Dohlsten M, Lando PA: Staphylococcal enterotoxin-dependent cell-mediated cytotoxity. Curr Top Microbiol Immunol 1991;174:81–92.
- Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P: Superantigens: Bacterial viral proteins that manipulate the immune system. Annu Rev Cell Biol 1993;9:101–128.
- Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T: Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 1995;92:9791–9795.
- Dohlsten M, Lando PA, Bjork P, Abrahmsen L, Ohlsson L, Lind P, Kalland T: Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 1995;41:162–168.
- Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL, Dohlsten M: Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 2001;85:129–136.
- Abrahmsen L: Superantigen engineering. Curr Opin Struct Biol 1995;5:464–470.
- Forsberg G, Forsgran M, Jaki M, Norin M, Sterky C, Enhorning A, Larsson K, Ericsson M, Bjork P: Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli. J Biol Chem 1997;272:12430–12436.
- Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M, Kalland T: Isolation, partial characterization and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 1993;268:24232–24241.
- Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT: The antitumor effects of the quinoline-3-carboxamine Linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 1992;52:3022–3028.
- Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
- Foon KA, Yannelli J, Bhattacharya-Chatterjee M: Colorectal cancer as a model for immunotherapy. Clin Cancer Res 1999;5:225–236.
- Riethmüller G, Johnson J: Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 1992;4:647–655.
Article / Publication Details
Received: October 02, 2002
Accepted: April 08, 2003
Published online: November 06, 2003
Issue release date: November – December
Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 1
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
